00897 Fubon Global Genomics and Immuno Biopharma ETF

Fund Details


Investment Objective

Fubon NYSE FactSet Global Genomics and Immuno Biopharma Exchange Traded Fund seeks investment results that closely track the performance of NYSE® FactSet® Global Genomics and Immuno Biopharma Index, before fees and expenses.

Fund Characteristic

  • Aims to capturing the market growth base on the upcoming biotechnology trend.
  • Selecting the constituent with big data picking process.
  • Selection 50 leading companies in Gene therapy, immunology, and bioengineering industries as fund constituents.

Index Description

The NYSE® FactSet® Global Genomics and Immuno Biopharma Index is a rules-based equity benchmark designed to track the performance of globally listed companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. The NYSE® FactSet® Global Genomics and Immuno Biopharma Index is compiled utilizing a methodology, RBICS (Revere Business Industry Classification System) classifications, and FactSet Supply Chain Relationships licensed from FactSet.

Principal Investment Strategy

Fubon Global Genomics and Immuno Biopharma ETF would allocate over 90% AUM in the constituents of NYSE® FactSet® Global Genomics and Immuno Biopharma Price Return Index and follow the index rebalance in order to deliver the corresponding performance of its underlying index.

Top Ten Holdings


    No. Stock Code Stock Name Weighting
    1 MRNA US MODERNA INC 6.79%
    2 BNTX US BIONTECH SE 5.99%
    3 MRK GY MERCK KGAA 5.50%
    4 NTLA US INTELLIA THERAPEUTICS INC 4.96%
    5 REGN US REGENERON PHARMACEUTICALS INC 4.94%
    6 SRPT US SAREPTA THERAPEUTICS INC 4.40%
    7 SGEN US SEAGEN INC 4.29%
    8 EVT GY EVOTEC SE 4.28%
    9 GILD US GILEAD SCIENCES INC 4.06%
    10 BPMC US BLUEPRINT MEDICINES CORP 3.98%

Source: ICE DATA INDICES,LLC Data as of 2021.11.30